Clinical Trial

The Effect of Cognitive Exercise on Upper Extremity Functions, Balance and Cognitive Functions in Multiple Sclerosis

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 19, 2024 (before its estimated May 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
Multiple sclerosis (MS) is a chronic, progressive, demyelinating disease characterized by myelin sheath damage in the central nervous system that affects more than 2.5 million people worldwide and is more common in young adults aged 20-40 years, especially in women. Like physical impairments, cognitive impairments are a common clinical finding in individuals with MS, both in the early and late stages of the disease. Individuals with MS with cognitive impairment have more difficulty than those without cognitive impairment in participating in social and occupational activities, finding a job, working and performing routine household activities. It is also known that there is a high percentage of individuals with MS with upper extremity involvement in the early stages of the disease. Functional problems in the upper extremities lead to restriction of activity and participation in individuals with MS. Although it is stated that there is a high rate of upper extremity problems in individuals with MS, it is seen that they are not sufficiently understood and analyzed. When the literature is examined; evidence-based studies examining the effect of cognitive exercise on motor functions in MS in addition to physical exercises are quite limited. In this context, the subject of this study is to examine the effect of cognitive rehabilitation on upper extremity functions, balance and cognitive functions in individuals with MS.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06511154
Lead Sponsor Ankara Yildirim Beyazıt University
Collaborators: Gulhane Training and Research Hospital
Conditions Multiple Sclerosis
Enrollment 32 participants
Start Date 2024-05-13
Primary Completion 2025-05-15 (estimated)
Study Completion 2025-06-15 (estimated)
Updated on ClinicalTrials.gov 2024-07-19